Liver health check: new drug tested in patients with impaired livers
NCT ID NCT05917938
First seen Feb 19, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study looked at how a single injection of the experimental drug NNC0194-0499 behaves in the body of people with various degrees of liver impairment and in healthy volunteers. The drug is being developed for fatty liver disease (NAFLD/NASH). 33 adults received one shot, and researchers measured drug levels and safety over 64 days. The goal was to understand how liver function affects the drug, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APEX Research
München, 81241, Germany
-
Cardiomedicum Sp. z o.o.
Krakow, 30-002, Poland
-
Summit Clinical Research s.r.o.
Bratislava, 83101, Slovakia
-
Summit Clinical Research s.r.o.
Malacky, 901 22, Slovakia
-
Uniwersyteckie Centrum Kliniczne (UCK)
Gdansk, 80-214, Poland
Conditions
Explore the condition pages connected to this study.